- In May 2023, the U.S. Food and Drug Administration (FDA) approved AYVAKIT® (avapritinib) for the treatment of indolent systemic mastocytosis (ISM), as announced by Blueprint Medicines Corporation. This approval makes it the first and only FDA-approved medication for ISM, offering a new treatment option for patients in the United States. The availability of AYVAKIT® represents a significant milestone in the management of this rare condition
- In June 2021, Blueprint Medicines Corporation received FDA approval for its drug candidate Apritinib, marketed as Ayvakit, for the treatment of advanced systemic mastocytosis in adult patients. This approval covers various forms of the disease, including mast cell leukemia, systemic mastocytosis with an associated hematological neoplasm, and aggressive systemic mastocytosis. The approval marks a significant advancement in treatment options for patients suffering from these severe forms of mastocytosis
